Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer
- Document radiologic and/or tumor marker response to cryotherapy of tumor lesions
followed by cyclophosphamide.
OUTLINE: This is a pilot study.
Patients undergo percutaneous biopsy of the targeted lesion prior to cryoablation. Patients
then undergo percutaneous or open cryotherapy of the largest or most accessible lesion on
day 0. On day 3, patients receive cyclophosphamide IV over 1 hour.
Tumor markers (if applicable) are assessed at baseline and monthly during study until marker
After completion of study therapy, patients are followed periodically for up to 3 years.
Primary Purpose: Treatment
Safety, in terms of absences of severe adverse events (SAE) and unacceptable toxicity
Ronald Rodriguez, MD, PhD
Brady Urological Institute at Johns Hopkins Hospital
|Brady Urological Institute at Johns Hopkins Hospital||Baltimore, Maryland 21205|